Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2023 Jan 19;24(3):1982.
doi: 10.3390/ijms24031982.

Eosinophilic Fasciitis: Current and Remaining Challenges

Diana Mazilu  1   2 , Laura Alina Boltașiu Tătaru  1 , Denise-Ani Mardale  1   2 , Maria Silviana Bijă  1 , Sermina Ismail  1 , Violeta Zanfir  1 , Florentina Negoi  1 , Andra Rodica Balanescu  1   2
Affiliations
Review

Eosinophilic Fasciitis: Current and Remaining Challenges

Diana Mazilu et al. Int J Mol Sci. .

Abstract

Eosinophilic fasciitis (EF), defined as diffuse fasciitis with eosinophilia by Shulman in 1974, is a disease with unknown etiology and whose pathogenesis is still being researched. The diagnosis is based on the clinical aspects (skin induration with an "orange peel" appearance), the lab results (eosinophilia, increased inflammatory markers), the skin biopsy with the pathognomonic histopathological result, as well as the typical MRI changes. The treatment includes glucocorticoids and immunosuppressive drugs. Due to severe refractory cases, the treatment remains a challenge. EF is still a disease with potential for further research.

Keywords: Shulman; eosinophilic fasciitis; systemic sclerosis.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

References

    1. Watanabe S., Kondo M., Ichishi M., Hayashi A., Matsushima Y., Hirokawa Y., Habe K., Yamanaka K. Eosinophilic fasciitis induced by a game of drumming probably via type 2 innate immunity. Int. J. Rheum. Dis. 2022;25:364–366. doi: 10.1111/1756-185X.14284. - DOI - PubMed
    1. le Tallec E., Lescoat A., Ballerie A. Eosinophilic Fasciitis Triggered by Nivolumab: A Remarkable Efficacy of the mTOR Inhibitor Sirolimus. J. Thorac. Oncol. 2020;15:e29–e30. doi: 10.1016/j.jtho.2019.09.011. - DOI - PubMed
    1. Chan K.K., Magro C., Shoushtari A., Rudin C., Rotemberg V., Rossi A., Lezcano C., Carrino J., Fernandez D., Postow M.A., et al. Eosinophilic Fasciitis Following Checkpoint Inhibitor Therapy: Four Cases and a Review of Literature. Oncologist. 2020;25:140–149. doi: 10.1634/theoncologist.2019-0508. - DOI - PMC - PubMed
    1. Teboul A., Chouchana L., Durrieu G., Eftekhari P., Treluyer J.-M., Mouthon L., Chaigne B. Drug-induced eosinophilic fasciitis: A dual pharmacovigilance analysis. J. Am. Acad. Dermatol. 2022;86:1372–1375. doi: 10.1016/j.jaad.2021.05.030. - DOI - PubMed
    1. Wang G., Zhuo N., Wen Z. Eosinophilic fasciitis induced by certolizumab pegol: Association or coincidence? Clin. Exp. Rheumatol. 2022. online ahead of print . - DOI - PubMed

Substances

Supplementary concepts